Head-to-head evidence
Afatinib vs Dacomitinib PF-00299804
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR/HER1, HER2, HER4 · full Non-Small Cell Lung Cancer pipeline
Afatinib · Gilotrif
Marketed by Boehringer Ingelheim
NCT00949650 · Phase 3 · completed
The study randomly assigned 345 participants to afatinib or active chemotherapy, but it was open-label rather than blinded. Its hard clinical primary endpoint, centrally assessed progression-free survival, was statistically significantly better with afatinib, but the lack of blinding limits the strength of the evidence.
Next expected readout: December 2026 · NCT04413201 (registry estimate)
Dacomitinib PF-00299804
Marketed by Pfizer
NCT01774721 · Phase 3 · completed
The 452 participants were randomly assigned to dacomitinib or the active comparator gefitinib, but the study was open-label rather than double-blinded. The hard clinical primary endpoint, independently assessed progression-free survival, was met in favor of dacomitinib, but the lack of blinding limits the strength of the evidence.
Next expected readout: April 2027 · NCT04946968 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Afatinib's landscape · Dacomitinib PF-00299804's landscape